<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Amyloid beta(40) (Abeta(40)) is the most abundant Abeta <z:chebi fb="7" ids="16670">peptide</z:chebi> in the brain </plain></SENT>
<SENT sid="1" pm="."><plain>The cerebrospinal fluid (CSF) level of Abeta(40) might therefore be considered to most closely reflect the total Abeta load in the brain </plain></SENT>
<SENT sid="2" pm="."><plain>Both in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and in <z:mpath ids='MPATH_458'>normal</z:mpath> aging the Abeta load in the brain has a large inter-individual variability </plain></SENT>
<SENT sid="3" pm="."><plain>Relating Abeta(42) to Abeta(40) levels might consequently provide a more valid measure for reflecting the change in Abeta metabolism in <z:hpo ids='HP_0000726'>dementia</z:hpo> patients than the CSF Abeta(42) concentrations alone </plain></SENT>
<SENT sid="4" pm="."><plain>This measure may also improve differential diagnosis between AD and other <z:hpo ids='HP_0000726'>dementia</z:hpo> syndromes, such as vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>), and <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> (FTD) </plain></SENT>
<SENT sid="5" pm="."><plain>OBJECTIVE: To investigate the diagnostic value of the CSF Abeta(42)/Abeta(40) ratio in differentiating AD from controls, VaD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and FTD </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS: We analysed the CSF Abeta(42)/Abeta(40) ratio, phosphorylated tau(181) and total tau in 69 patients with AD, 26 patients with VaD, 16 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, 27 patients with FTD, and 47 controls </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Mean Abeta(40) levels were 2850 pg/ml in VaD and 2830 pg/ml in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> patients, both significantly lower than in AD patients (3698 pg/ml; p&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Abeta(40) levels in AD patients were not significantly different from those in controls (4035 pg/ml; p=0.384) </plain></SENT>
<SENT sid="9" pm="."><plain>The Abeta(42)/Abeta(40) ratio was significantly lower in AD patients than in <z:hpo ids='HP_0000001'>all</z:hpo> other groups (p &lt;0.001, ANCOVA) </plain></SENT>
<SENT sid="10" pm="."><plain>Differentiating AD from VaD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and non-AD <z:hpo ids='HP_0000726'>dementia</z:hpo> improved when the Abeta(42)/Abeta(40) ratio was used instead of Abeta(42) concentrations alone (p&lt;0.01) The Abeta(42)/Abeta(40) ratio performed equally well as the combination of Abeta(42), phosphorylated tau(181) and total tau in differentiating AD from FTD and non-AD <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The diagnostic performance of the latter combination was not improved when the Abeta(42)/Abeta(40) ratio was used instead of Abeta(42) alone </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The CSF Abeta42/Abeta40 ratio improves differentiation of AD patients from VaD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and non-AD <z:hpo ids='HP_0000726'>dementia</z:hpo> patients, when compared to Abeta42 alone, and is a more easily interpretable alternative to the combination of Abeta42, p-tau and t-tau when differentiating AD from either FTD or non-AD <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>